New markers for minimal residual disease detection in acute lymphoblastic leukemia

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

(2010) V. Conter et al.   BLOOD

Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia

(2010) P. Stow et al.   BLOOD

Adult acute lymphoblastic leukemia

(2010) Stefan Faderl et al.   CANCER

MLL-Rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-Binding Protein Galectin-1

(2010) P. Juszczynski et al.   CLINICAL CANCER RESEARCH

Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation

(2010) A C Lankester et al.   LEUKEMIA

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

(2009) R. Bassan et al.   BLOOD

Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells

(2009) Liqing Jin et al.   Cell Stem Cell

Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia

(2009) M. Djokic et al.   HAEMATOLOGICA

Role of Minimal Residual Disease Monitoring in Adult and Pediatric Acute Lymphoblastic Leukemia

(2009) Dario Campana   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow

(2009) Giuseppe Basso et al.   JOURNAL OF CLINICAL ONCOLOGY

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

(2009) M Brüggemann et al.   LEUKEMIA

Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000

(2009) A Möricke et al.   LEUKEMIA

Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation

(2009) Ching-Hon Pui et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

(2008) M. J. Borowitz et al.   BLOOD

Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study

(2008) Jerzy Holowiecki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: Potential usefulness in minimal residual disease detection

(2008) Joseph A. DiGiuseppe et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

(2008) Elizabeth A. Raetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group

(2008) Peter Bader et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal residual disease is an important predictive factor of outcome in children with relapsed ‘high-risk’ acute lymphoblastic leukemia

(2008) M Paganin et al.   LEUKEMIA

Treatment of Adult Acute Lymphoblastic Leukemia

(2008) Nicola Gökbuget et al.   SEMINARS IN HEMATOLOGY